Small-cell carcinoma

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Retrieved on: 
Friday, April 5, 2024
Research, FDA, Clinical Trials, Biometrics, Health, Pharmaceutical, General Health, Science, Oncology, Lung cancer, Chemoradiotherapy, CRT, Small-cell carcinoma, Radiation, AstraZeneca, Survival, NSCLC, Immunotherapy, Disease, Infection, Carcinoma, Incidence, Progression-free survival, Patient, Warning, Doctor of Philosophy, Prednisone, Adrenocorticotropic hormone, Creatinine, Prognosis, PFS, Recurrence, ACTH, Administration, Pneumonitis, SCLC, Vaccine

Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.

Key Points: 
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, MHC, Neoplasm, SCLC, NCI, NE, Society for Immunotherapy of Cancer, Medicine, Carcinoma, Cell, Glomus tumor, SITC, Immunotherapy, Small-cell carcinoma, NK, Cancer, Society, ICB, Patient, Abstract, Bangladesh Technical Education Board, Pharmaceutical industry, Medical imaging, ImmunityBio COVID-19 vaccine

Small cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) carcinoma and has few treatment options.

Key Points: 
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) carcinoma and has few treatment options.
  • In the new study, the killing capacity of M-ceNK cells was assessed in four SCLC cell lines representing the major molecular subtypes.
  • The M-ceNK cells were highly cytotoxic against all types of SCLC models, as well as against prostate neuroendocrine cancer.
  • “We are encouraged by the data coming out of this study and we look forward to assessing the potential for M-ceNK therapy in other tumor types.”

US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer

Retrieved on: 
Friday, July 21, 2023
Carcinoma, Nanoparticle, Marketing, API, Clinical trial, Treatment of lung cancer, FDA, Small-cell carcinoma, Pharmaceutical industry, IND

SNB-101 showed excellent efficacy in animal small cell lung cancer models, and based on this, it has been designated as an orphan drug by the US FDA after application in April and review.

Key Points: 
  • SNB-101 showed excellent efficacy in animal small cell lung cancer models, and based on this, it has been designated as an orphan drug by the US FDA after application in April and review.
  • Small cell lung cancer accounts for 15-20% of all lung cancers with a very poor prognosis.
  • Orphan drug designation is a program where the FDA facilitates the development and approval of treatments for rare/incurable or life-threatening diseases.
  • SN Bioscience expects the designation as an orphan drug to accelerate the development of SNB-101, which is being developed as a treatment for orphan drugs including small cell lung cancer.

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer

Retrieved on: 
Thursday, July 20, 2023
Maintenance, Progression-free survival, Survival, OS, Platinum, Cancer, Lung cancer, Toxicity, PFS, Global Research, SCLC, Development, SSE, Radiation, Shanda, HIV disease progression rates, Patient, National Medical Products Administration, CSCO, Mortality, Diagnosis, Chinese, PD-1, Metastasis, Safety, Small-cell carcinoma, Pharmaceutical industry, Medical imaging

Small cell lung cancer (“SCLC”) is the most aggressive subtype of lung cancer, accounting for approximately 15%-20% of all lung cancer cases with characteristics including rapid progression, early metastasis and a poor prognosis.

Key Points: 
  • Small cell lung cancer (“SCLC”) is the most aggressive subtype of lung cancer, accounting for approximately 15%-20% of all lung cancer cases with characteristics including rapid progression, early metastasis and a poor prognosis.
  • SCLC is divided into limited-stage small cell lung cancer (“LS-SCLC”) and ES-SCLC.
  • The supplemental new drug application is mainly based on EXTENTORCH (NCT04012606), a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical study.
  • In lung cancer alone, toripalimab has been involved in 3 successful large-scale phase 3 clinical trials encompassing diverse subtypes and stages of disease progression.

Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer

Retrieved on: 
Thursday, July 13, 2023
Pharmacy, Liquid biopsy, Cancer, Lung cancer, NSCLC, Biomarker, Chinese, Nen language (Papuan), SCLC, Silicon, CTC, Protein, RUO, DLL3, Patient, Physician, Colorectal cancer, MSB, Research, FDA, Small-cell carcinoma, Disease, Pharmaceutical industry, Medical imaging, Statera BioPharma

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., July 13, 2023 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single cell technologies, announced today the availability of its new CELLSEARCH CTC lab service to detect expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream. This biomarker is mainly expressed in difficult-to-treat cancers. The new MSB lab service opens the door to the development of further minimally invasive tests that leverage the prognostic and predictive value of biomarkers in medical settings with high unmet needs.

Key Points: 
  • This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service in North America and Europe.
  • According to Ralf Schoenbrunner, Chief Global R&D Officer of Menarini Silicon Biosystems, "We have the capability to develop such tests very quickly.
  • Lung cancer is the second most common cancer worldwide with over 2.2 million cases in 2020.
  • Small cell lung cancer (SCLC) represents about 15%[1] of these cancers and is more aggressive than the more prevalent Non-Small Cell Lung Cancer (NSCLC) and often diagnosed in the late stage of the disease.

Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer

Retrieved on: 
Thursday, July 13, 2023
Pharmacy, Liquid biopsy, Cancer, Lung cancer, NSCLC, Biomarker, Chinese, Nen language (Papuan), SCLC, Silicon, CTC, Protein, RUO, DLL3, Patient, Physician, Colorectal cancer, MSB, Research, FDA, Small-cell carcinoma, Disease, Pharmaceutical industry, Medical imaging, Statera BioPharma

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., July 13, 2023 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single cell technologies, announced today the availability of its new CELLSEARCH CTC lab service to detect expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream. This biomarker is mainly expressed in difficult-to-treat cancers. The new MSB lab service opens the door to the development of further minimally invasive tests that leverage the prognostic and predictive value of biomarkers in medical settings with high unmet needs.

Key Points: 
  • This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service in North America and Europe.
  • According to Ralf Schoenbrunner, Chief Global R&D Officer of Menarini Silicon Biosystems, "We have the capability to develop such tests very quickly.
  • Lung cancer is the second most common cancer worldwide with over 2.2 million cases in 2020.
  • Small cell lung cancer (SCLC) represents about 15%[1] of these cancers and is more aggressive than the more prevalent Non-Small Cell Lung Cancer (NSCLC) and often diagnosed in the late stage of the disease.

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

Retrieved on: 
Thursday, June 29, 2023
Carcinoma, Progression-free survival, Survival, Lung cancer, Cancer, Cardiac resynchronization therapy, Prognosis, SOC, NSCLC, Trial of the century, Global Research, SCLC, BTLA, Junshi, SSE, Development, HIV disease progression rates, Patient, Standard of care, Mortality, Hospital, MOS, Chemoradiotherapy, CRT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Small-cell carcinoma, Pharmaceutical industry

According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China.

Key Points: 
  • According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China.
  • Lung cancer can be broadly categorized into non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”), based on cell type.
  • Specifically, small cell lung cancer is the most invasive subtype of lung cancer, accounting for about 15%-20% of all lung cancer cases with characteristics such as rapid progression, early metastasis, and poor prognosis.
  • Small cell lung cancer includes limited-stage small cell lung cancer (“LS-SCLC”) and extensive-stage small cell lung cancer, and LS-SCLC accounts for about one-third of all small cell lung cancer cases.

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

Retrieved on: 
Monday, November 21, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Lung cancer, Clinical trial, Squamous cell carcinoma, Small-cell carcinoma, Drug, Cancer, Government, NK, Large cell neuroendocrine carcinoma of the lung, Prostate cancer, SNAI1, Investigational New Drug, Safety, Security (finance), IND, SCLC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Maintenance, Annual report, Legend, Wilms' tumor, Therapy, Regulation, COVID-19, Diagnosis, American Cancer Society, Food, Patient, United, Pharmaceutical industry, Uranium, Vaccine

On average, only seven percent of patients with SCLC are alive five years after receiving their diagnosis, said Lida Pacaud, M.D., Vice-President of Clinical Development at Legend Biotech.

Key Points: 
  • On average, only seven percent of patients with SCLC are alive five years after receiving their diagnosis, said Lida Pacaud, M.D., Vice-President of Clinical Development at Legend Biotech.
  • Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
  • 1 Furuta M. DLL3 regulates the migration and invasion of small cell lung cancer by modulating SNAI1.
  • Small cell lung cancer: where do we go from here?

STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING

Retrieved on: 
Monday, November 14, 2022
Jazz Pharmaceuticals, MRCPCH, Doctor of Philosophy, PSA, KRAS, Tobacco Products Scientific Advisory Committee, Radon, FAC, SU2C, Entertainment Industry Foundation, Awareness, Partnership, Safety, Non-Smokers' Rights Association, Cancer, Research, Noreen Fraser Foundation, Smoking, Squamous cell carcinoma, Multimedia, Lung cancer, Patient, Small-cell carcinoma, Air pollution, CEO, Stand Up to Cancer, Large-cell lung carcinoma, Diagnosis, Radio, Young adult, Disease, Smoke, Pharmaceutical industry, Black, Adolescence

The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options.

Key Points: 
  • The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options.
  • "Additionally, we are incredibly thankful to Jazz Pharmaceuticals for the company's support of SU2C's Catalystprogram, including research to investigate potential new treatments for non-small cell lung cancer."
  • "Jazz is committed to transforming the lives of patients and their families, and our collaboration with Stand Up To Cancer on this PSA campaign aims to spread awareness of small cell lung cancer and encourage early screening.
  • Stand Up To Cancer recently announced the funding of three SU2C Catalyst research projects with support from Jazz Pharmaceuticals.